The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Anti-Depressant-Global Market Insights and Sales Trends 2025
Synopsis
Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive–compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraine, attention-deficit hyperactivity disorder (ADHD), addiction, dependence, and sleep disorders. They may be prescribed alone or in combination with other medications.
The global Anti-Depressant market size is expected to reach US$ 18090 million by 2029, growing at a CAGR of 3.3% from 2023 to 2029. The market is mainly driven by the significant applications of Anti-Depressant in various end use industries. The expanding demands from the Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder and Panic Disorder, are propelling Anti-Depressant market. Tricyclic Antidepressants, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Selective Serotonin Reuptake Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Anti-Depressant, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Anti-Depressant market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Anti-Depressant market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Anti-Depressant sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Anti-Depressant covered in this report include Alkermes, Allergan, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Lundbeck, Merck, Pfizer and Teva Pharmaceutical Industries, etc.
The global Anti-Depressant market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Alkermes
Allergan
Bristol-Myers Squibb
Eli Lilly and Company
GlaxoSmithKline
Lundbeck
Merck
Pfizer
Teva Pharmaceutical Industries
Takeda Pharmaceutical
Global Anti-Depressant market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Anti-Depressant market, Segment by Type:
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin-Norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Serotonin Antagonist
Reuptake Inhibitors
Others
Global Anti-Depressant market, by Application
Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Anti-Depressant manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Anti-Depressant in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Antidepressants are drugs used for the treatment of major depressive disorder and other conditions, including dysthymia, anxiety disorders, obsessive–compulsive disorder, eating disorders, chronic pain, neuropathic pain and, in some cases, dysmenorrhoea, snoring, migraine, attention-deficit hyperactivity disorder (ADHD), addiction, dependence, and sleep disorders. They may be prescribed alone or in combination with other medications.
The global Anti-Depressant market size is expected to reach US$ 18090 million by 2029, growing at a CAGR of 3.3% from 2023 to 2029. The market is mainly driven by the significant applications of Anti-Depressant in various end use industries. The expanding demands from the Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder and Panic Disorder, are propelling Anti-Depressant market. Tricyclic Antidepressants, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Selective Serotonin Reuptake Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Anti-Depressant, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Anti-Depressant market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Anti-Depressant market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Anti-Depressant sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Anti-Depressant covered in this report include Alkermes, Allergan, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Lundbeck, Merck, Pfizer and Teva Pharmaceutical Industries, etc.
The global Anti-Depressant market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Alkermes
Allergan
Bristol-Myers Squibb
Eli Lilly and Company
GlaxoSmithKline
Lundbeck
Merck
Pfizer
Teva Pharmaceutical Industries
Takeda Pharmaceutical
Global Anti-Depressant market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Anti-Depressant market, Segment by Type:
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin-Norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Serotonin Antagonist
Reuptake Inhibitors
Others
Global Anti-Depressant market, by Application
Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Anti-Depressant manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Anti-Depressant in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Anti-Depressant Market Overview
1.1 Anti-Depressant Product Overview
1.2 Anti-Depressant Market Segment by Type
1.2.1 Tricyclic Antidepressants
1.2.2 Selective Serotonin Reuptake Inhibitors
1.2.3 Serotonin-Norepinephrine Reuptake Inhibitors
1.2.4 Monoamine Oxidase Inhibitors
1.2.5 Serotonin Antagonist
1.2.6 Reuptake Inhibitors
1.2.7 Others
1.3 Global Anti-Depressant Market Size by Type
1.3.1 Global Anti-Depressant Market Size Overview by Type (2018-2029)
1.3.2 Global Anti-Depressant Historic Market Size Review by Type (2018-2023)
1.3.3 Global Anti-Depressant Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Anti-Depressant Sales Breakdown by Type (2018-2023)
1.4.2 Europe Anti-Depressant Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Anti-Depressant Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Anti-Depressant Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Anti-Depressant Sales Breakdown by Type (2018-2023)
2 Global Anti-Depressant Market Competition by Company
2.1 Global Top Players by Anti-Depressant Sales (2018-2023)
2.2 Global Top Players by Anti-Depressant Revenue (2018-2023)
2.3 Global Top Players by Anti-Depressant Price (2018-2023)
2.4 Global Top Manufacturers Anti-Depressant Manufacturing Base Distribution, Sales Area, Product Type
2.5 Anti-Depressant Market Competitive Situation and Trends
2.5.1 Anti-Depressant Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Anti-Depressant Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anti-Depressant as of 2022)
2.7 Date of Key Manufacturers Enter into Anti-Depressant Market
2.8 Key Manufacturers Anti-Depressant Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Anti-Depressant Status and Outlook by Region
3.1 Global Anti-Depressant Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Anti-Depressant Historic Market Size by Region
3.2.1 Global Anti-Depressant Sales in Volume by Region (2018-2023)
3.2.2 Global Anti-Depressant Sales in Value by Region (2018-2023)
3.2.3 Global Anti-Depressant Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Anti-Depressant Forecasted Market Size by Region
3.3.1 Global Anti-Depressant Sales in Volume by Region (2024-2029)
3.3.2 Global Anti-Depressant Sales in Value by Region (2024-2029)
3.3.3 Global Anti-Depressant Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Anti-Depressant by Application
4.1 Anti-Depressant Market Segment by Application
4.1.1 Major Depressive Disorder
4.1.2 Obsessive-Compulsive Disorder
4.1.3 Generalized Anxiety Disorder
4.1.4 Panic Disorder
4.1.5 Others
4.2 Global Anti-Depressant Market Size by Application
4.2.1 Global Anti-Depressant Market Size Overview by Application (2018-2029)
4.2.2 Global Anti-Depressant Historic Market Size Review by Application (2018-2023)
4.2.3 Global Anti-Depressant Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Anti-Depressant Sales Breakdown by Application (2018-2023)
4.3.2 Europe Anti-Depressant Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Anti-Depressant Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Anti-Depressant Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Anti-Depressant Sales Breakdown by Application (2018-2023)
5 North America Anti-Depressant by Country
5.1 North America Anti-Depressant Historic Market Size by Country
5.1.1 North America Anti-Depressant Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Anti-Depressant Sales in Volume by Country (2018-2023)
5.1.3 North America Anti-Depressant Sales in Value by Country (2018-2023)
5.2 North America Anti-Depressant Forecasted Market Size by Country
5.2.1 North America Anti-Depressant Sales in Volume by Country (2024-2029)
5.2.2 North America Anti-Depressant Sales in Value by Country (2024-2029)
6 Europe Anti-Depressant by Country
6.1 Europe Anti-Depressant Historic Market Size by Country
6.1.1 Europe Anti-Depressant Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Anti-Depressant Sales in Volume by Country (2018-2023)
6.1.3 Europe Anti-Depressant Sales in Value by Country (2018-2023)
6.2 Europe Anti-Depressant Forecasted Market Size by Country
6.2.1 Europe Anti-Depressant Sales in Volume by Country (2024-2029)
6.2.2 Europe Anti-Depressant Sales in Value by Country (2024-2029)
7 Asia-Pacific Anti-Depressant by Region
7.1 Asia-Pacific Anti-Depressant Historic Market Size by Region
7.1.1 Asia-Pacific Anti-Depressant Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Anti-Depressant Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Anti-Depressant Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Anti-Depressant Forecasted Market Size by Region
7.2.1 Asia-Pacific Anti-Depressant Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Anti-Depressant Sales in Value by Region (2024-2029)
8 Latin America Anti-Depressant by Country
8.1 Latin America Anti-Depressant Historic Market Size by Country
8.1.1 Latin America Anti-Depressant Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Anti-Depressant Sales in Volume by Country (2018-2023)
8.1.3 Latin America Anti-Depressant Sales in Value by Country (2018-2023)
8.2 Latin America Anti-Depressant Forecasted Market Size by Country
8.2.1 Latin America Anti-Depressant Sales in Volume by Country (2024-2029)
8.2.2 Latin America Anti-Depressant Sales in Value by Country (2024-2029)
9 Middle East and Africa Anti-Depressant by Country
9.1 Middle East and Africa Anti-Depressant Historic Market Size by Country
9.1.1 Middle East and Africa Anti-Depressant Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Anti-Depressant Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Anti-Depressant Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Anti-Depressant Forecasted Market Size by Country
9.2.1 Middle East and Africa Anti-Depressant Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Anti-Depressant Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Alkermes
10.1.1 Alkermes Company Information
10.1.2 Alkermes Introduction and Business Overview
10.1.3 Alkermes Anti-Depressant Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Alkermes Anti-Depressant Products Offered
10.1.5 Alkermes Recent Development
10.2 Allergan
10.2.1 Allergan Company Information
10.2.2 Allergan Introduction and Business Overview
10.2.3 Allergan Anti-Depressant Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Allergan Anti-Depressant Products Offered
10.2.5 Allergan Recent Development
10.3 Bristol-Myers Squibb
10.3.1 Bristol-Myers Squibb Company Information
10.3.2 Bristol-Myers Squibb Introduction and Business Overview
10.3.3 Bristol-Myers Squibb Anti-Depressant Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Bristol-Myers Squibb Anti-Depressant Products Offered
10.3.5 Bristol-Myers Squibb Recent Development
10.4 Eli Lilly and Company
10.4.1 Eli Lilly and Company Company Information
10.4.2 Eli Lilly and Company Introduction and Business Overview
10.4.3 Eli Lilly and Company Anti-Depressant Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Eli Lilly and Company Anti-Depressant Products Offered
10.4.5 Eli Lilly and Company Recent Development
10.5 GlaxoSmithKline
10.5.1 GlaxoSmithKline Company Information
10.5.2 GlaxoSmithKline Introduction and Business Overview
10.5.3 GlaxoSmithKline Anti-Depressant Sales, Revenue and Gross Margin (2018-2023)
10.5.4 GlaxoSmithKline Anti-Depressant Products Offered
10.5.5 GlaxoSmithKline Recent Development
10.6 Lundbeck
10.6.1 Lundbeck Company Information
10.6.2 Lundbeck Introduction and Business Overview
10.6.3 Lundbeck Anti-Depressant Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Lundbeck Anti-Depressant Products Offered
10.6.5 Lundbeck Recent Development
10.7 Merck
10.7.1 Merck Company Information
10.7.2 Merck Introduction and Business Overview
10.7.3 Merck Anti-Depressant Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Merck Anti-Depressant Products Offered
10.7.5 Merck Recent Development
10.8 Pfizer
10.8.1 Pfizer Company Information
10.8.2 Pfizer Introduction and Business Overview
10.8.3 Pfizer Anti-Depressant Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Pfizer Anti-Depressant Products Offered
10.8.5 Pfizer Recent Development
10.9 Teva Pharmaceutical Industries
10.9.1 Teva Pharmaceutical Industries Company Information
10.9.2 Teva Pharmaceutical Industries Introduction and Business Overview
10.9.3 Teva Pharmaceutical Industries Anti-Depressant Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Teva Pharmaceutical Industries Anti-Depressant Products Offered
10.9.5 Teva Pharmaceutical Industries Recent Development
10.10 Takeda Pharmaceutical
10.10.1 Takeda Pharmaceutical Company Information
10.10.2 Takeda Pharmaceutical Introduction and Business Overview
10.10.3 Takeda Pharmaceutical Anti-Depressant Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Takeda Pharmaceutical Anti-Depressant Products Offered
10.10.5 Takeda Pharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Anti-Depressant Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Anti-Depressant Industrial Chain Analysis
11.4 Anti-Depressant Market Dynamics
11.4.1 Anti-Depressant Industry Trends
11.4.2 Anti-Depressant Market Drivers
11.4.3 Anti-Depressant Market Challenges
11.4.4 Anti-Depressant Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Anti-Depressant Distributors
12.3 Anti-Depressant Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
